A Phase 2 Bridging Study to Assess the New Formulation of ETVAX

Inclusion Criteria: * Male or female aged 18-50 years, inclusive at the time of signing the informed consent. * Healthy constitution as established by medical history and physical examination. * Willing and able to give written informed consent for participation in the study. * Able to comply with study activities, as judged by the Investigator. * Female Participants: * Women of child-bearing potential (for definition see Section 9.3.6 in the protocol): * Have to agree to use an acceptable birth control method during participation in the investigation (see Section 9.3.6). * A negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at Visit 2/Day 1 will be required. * Male Participants: * Have to agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined in Section 9.3.6 Exclusion criteria * An acute or chronic medical condition that, in the opinion of the investigator/physician, would render ingestion of the investigational products unsafe or would interfere with the evaluation of responses. This includes, but is not limited to gastrointestinal diseases, and autoimmune diseases. * Current malignancy or history of malignancy during the last five years, based on anamnesis. * Gastroenteritis within two weeks prior to vaccination. * Regular use of laxatives, antacids or other agents that lower stomach acidity. * Any planned major surgery during the duration of the study.…